Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study

Benzer Materyaller

• Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
  Yazar:: Braun, Jürgen, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study
  Yazar:: Kivitz, Alan J., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
  Yazar:: Baraliakos, Xenofon, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2
  Yazar:: Marzo-Ortega, Helena, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
  Yazar:: Braun, Jürgen, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)